Roth Capital Reiterates Buy On Lemaitre Vascular Shares, $10 PT
In a research report issued today, Roth Capital analyst Chris Lewis reiterated a Buy rating on Lemaitre Vascular (NASDAQ:LMAT) with a price target of $10.00.
Lewis noted, “LMAT announced 3Q revenues above expectations and inline EPS, and slightly ticked up its 2014 outlook. We believe LMAT is well-positioned to deliver at least 10% reported revenue growth and 20% operating income growth in 2015. This outlook, paired with an acquisitive business model, should allow LMAT to garner a valuation in line with its peers, in our opinion. As such, we continue to view LMAT’s risk-reward profile as favorable.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Chris Lewis has a total average return of -5.2% and a 47.7% success rate. Lewis has a 1.3% average return when recommending LMAT, and is ranked #3101 out of 3350 analysts.